Navigation Links
Codexis Names Vice President, Intellectual Property
Date:9/23/2008

REDWOOD CITY, Calif., Sept. 23 /PRNewswire/ -- Codexis, Inc., today announced the appointment of Lynn Marcus-Wyner, Ph.D., as Vice President, Intellectual Property. She will be responsible for managing the company's intellectual property strategy, activities, and patent portfolio and will report to Douglas Sheehy, Vice President, General Counsel and Secretary.

Dr. Marcus-Wyner joins Codexis from Danisco A/S, where as Senior Director, Intellectual Assets US, she managed the United States patent department of the Genencor division. Previously, she was in private intellectual property law practice representing clients, including Genencor International, Inc., and Novartis Corporation, and held a legal patent management position at Sandoz Agro Inc. Dr. Marcus-Wyner was also a Patent Attorney at Zeneca Inc. (formerly ICI Americas Inc). Dr. Marcus-Wyner has a J.D. from the University of the Pacific, McGeorge School of Law and a Ph.D. in plant physiology from the University of California, Davis. Prior to law school, Dr. Marcus-Wyner was an Assistant Professor in the Plant and Soil Science Department at the University of Massachusetts, Amherst.

"Building and protecting our intellectual property portfolio is a key success factor for Codexis," Mr. Sheehy said. "Dr. Marcus-Wyner has broad experience counseling life science and bioindustrial companies on intellectual property law matters, and brings a proven track record in managing this important function in our industry," Mr. Sheehy said. "We are very pleased to add her to the Codexis legal team."

Codexis is a leading developer of proprietary biocatalysts that the company believes have the potential to revolutionize chemistry-based manufacturing processes across a variety of industries. The company has used its technology platform to enable biocatalyst-based commercial-scale drug manufacturing processes and delivered biocatalysts and drug products to some of the world's leading pharmaceutical companies. Codexis has a funded research collaboration in the biofuels market, and the company is pursuing funded collaborations in several other bioindustrial markets, including carbon management, water treatment and chemicals.
CONTACT: Lyn Christenson, lyn.christenson@codexis.com,

650-421-8144, or Justin Jackson, jjackson@burnsmc.com,

Burns McClellan, 212-213-0006


'/>"/>
SOURCE Codexis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis, Arch Announce Expanded Collaboration
2. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Codexis Names David Anton VP Bioindustrials R&D
4. Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds
5. Rothwell, Wolf Elected to Codexis Board
6. Codexis Opens Singapore Laboratory
7. Bruce Pasternack Elected to Codexis Board
8. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
9. Codexis Appoints Singapore Laboratories Managing Director
10. Genstruct Names Louis Latino VP of Sales
11. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... India , February 17, 2017 ... report "Biomarkers Market by Product (Consumables, Service), Type ... Application (Diagnostics Development, Drug Discovery and Development, Disease-Risk) ... the market is projected to reach USD 53.34 ... 2016, growing at a CAGR of 13.8% during ...
(Date:2/16/2017)... ... February 16, 2017 , ... EIT Digital has ... at the agricultural industry. Pilot studies are about to get under way for the ... Data and 5G innovations. The concept is expected to be transferred eventually to other ...
(Date:2/16/2017)... Calif. , Feb. 16, 2017  ArmaGen, ... developing groundbreaking therapies to treat severe neurological disorders, ... children treated with AGT-181, the company,s investigational therapy ... (also known as mucopolysaccharidosis type I, or MPS ... 2 proof-of-concept (POC) study, presented today at the ...
(Date:2/16/2017)... UCHealth ( Aurora, Colorado ) becomes the ... management. In addition to optimizing care coordination for patients ... UCHealth looks to improve provider workflow by decreasing the ... Stephanie Brown, RN , Thoracic Nurse Navigator, says, "I ... spreadsheet, which was extremely arduous and susceptible to error.  ...
Breaking Biology Technology:
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:1/30/2017)... Jan. 30, 2017   Invitae Corporation (NYSE: ... genetic information companies, today announced that it will report ... provide 2017 guidance on Monday, February 13, 2017, and ... day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... will briefly review financial results, guidance, and recent developments ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds simple ... sock that monitors vital signs and alerts parents ... infant,s oxygen saturation level drops. But pediatric experts ... to parents, with no evidence of medical benefits, ... are marketed aggressively to parents of healthy babies, ...
Breaking Biology News(10 mins):